Literature DB >> 32706216

High thrombus burden despite thrombolytic therapy in ST-elevation myocardial infarction in a patient with COVID-19.

Gayatri Setia1, Jeffrey Tyler2, Alan Kwan2, Josh Faguet1, Shilpa Sharma2, Siddharth Singh2, Babak Azarbal2, Rose Tompkins2, Dinora Chinchilla3, Sara Ghandehari3.   

Abstract

Consideration of thrombolysis as first-line reperfusion therapy in patients with COVID-19 and STEMI is recommended by ACC/SCAI guidelines. We describe a patient with COVID-19, who presented with ST-elevation myocardial infarction and was treated with thrombolysis and anticoagulation. He was later found to have a significant persistent thrombus burden requiring thrombectomy and stent placement. Invasive hemodynamics on multiple high-dose pressers revealed a high cardiac output state with low systemic vascular resistance, consistent with distributive rather than cardiogenic shock. Our case illustrates that thrombolytic therapy alone may not be adequate in patients with STEMI and COVID-19, as well as the importance of early invasive hemodynamics in management of shock in patient with STEMI and COVID-19 infection.
© 2020 Setia et al. Published by IMR press.

Entities:  

Keywords:  COVID-19; ST-elevation myocardialzzm321990infarction; acute coronary syndrome; thrombolysis

Mesh:

Substances:

Year:  2020        PMID: 32706216     DOI: 10.31083/j.rcm.2020.02.92

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  2 in total

1.  COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception-A Systematic Review.

Authors:  Tissa Wijeratne; Sheila Gillard Crewther; Carmela Sales; Leila Karimi
Journal:  Front Neurol       Date:  2021-01-28       Impact factor: 4.003

Review 2.  A Review of Coronary Artery Thrombosis: A New Challenging Finding in COVID-19 Patients and ST-elevation Myocardial Infarction.

Authors:  Mohammad Kermani-Alghoraishi
Journal:  Curr Probl Cardiol       Date:  2020-11-02       Impact factor: 5.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.